• Tobias Ettl, Stephan Schwarz-Furlan, Martin Gosau, and Torsten E Reichert.
• Department of Oral and Maxillofacial Surgery, Regensburg University, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany. tobias.ettl@ukr.de
• Oral Maxillofac Surg. 2012 Sep 1; 16 (3): 267-83.

IntroductionSalivary gland carcinomas are rare tumours of heterogeneous morphology that require distinctive surgical and adjuvant therapy.MethodsRelevant studies were electronically searched in PubMed and reviewed for innovative and important information.ResultsRecent insights in genetic alterations like chromosomal aberrations, expression of receptor tyrosine kinases, malfunction of tumour suppressor genes or DNA promoter methylations increased the knowledge about aetiology and pathogenesis. New histological subtypes are recognised, and a three-tiered grading system seems reasonable. Ultrasound remains the basic diagnostic imaging procedure. New developments comprise the diffusion-weighed magnetic resonance imaging, while fluorodeoxyglucose positron emission tomography/computed tomography shows good diagnostic accuracy in detecting distant metastases and local recurrence. Fine-needle aspiration cytology helps in differentiating a neoplasia from a non-neoplastic lesion while being unreliable in recognising malignancy. In contrast, additional core needle biopsy and/or intraoperative frozen section diagnosis increase the accuracy in diagnosing a malignant lesion. Conservative parotid surgery with nerve monitoring remains state-of-the-art. Free flaps or musculoaponeurotic flaps are proposed for prevention of Frey's syndrome. As parotid cancer often shows skip metastases, complete ipsilateral neck dissection (level I-V) is indicated particularly in high-grade lesions. Adjuvant radio(chemo)therapy increases local tumour control, whereas overall survival is not necessarily improved. Current results of systemic chemotherapy or targeted therapy in advanced tumour stages are disappointing.ConclusionDespite several developments, salivary gland carcinomas remain a heterogeneous group of tumours challenging both pathologists and clinicians.

36 keywords...

hide…